Trimeric glycosylphosphatidylinositol-anchored HCDR3 of broadly neutralizing antibody PG16 Is a potent HIV-1 entry inhibitor

Journal of Virology

Volumn 87, Issue 3, 2013, Pages 1899-1905

  Liu, Lihong ^a   Wang, Weiming ^a   Yang, Lifei ^a   Ren, Huanhuan ^a   Kimata, Jason T ^b   Zhou, Paul ^a  

^a INSTITUTE PASTEUR OF SHANGHAI   (China)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED HCDR3; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; NEUTRALIZING ANTIBODY PG16; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ARTICLE; BETA SHEET; BINDING AFFINITY; CELL SURFACE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROGEN BOND; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIMIAN IMMUNODEFICIENCY VIRUS; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS NEUTRALIZATION; VIRUS REPLICATION; VIRUS STRAIN;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; GLYCOSYLPHOSPHATIDYLINOSITOLS; HIV ANTIBODIES; HIV FUSION INHIBITORS; HIV-1; VIRUS INTERNALIZATION;

EID: 84873033034     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01038-12     Document Type: Article

References (27)

1. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289.
2. Pancera M, McLellan JS, Wu X, Zhu J, Changela A, Schmidt SD, Yang Y, Zhou T, Phogat S, Mascola JR, Kwong PD. 2010. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structurefunction analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J. Virol. 84:8098-8110.
3. Pejchal R, Walker LM, Stanfield RL, Phogat SK, Koff WC, Poignard P, Burton DR, Wilson IA. 2010. Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc. Natl. Acad. Sci. U. S. A. 107:11483-11488.
4. Liu L, Wen M, Wang W, Wang S, Yang L, Liu Y, Qian M, Zhang L, Shao Y, Kimata JT, Zhou P. 2011. Potent and broad anti-HIV-1 activity exhibited by a glycosyl-phosphatidylinositol-anchored peptide derived from the CDR H3 of broadly neutralizing antibody PG16. J. Virol. 85: 8467-8476.
5. Doores KJ, Burton DR. 2010. Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J. Virol. 84:10510 -10521.
6. Medof ME, Kinoshita T, Nussenzweig V. 1984. Inhibition of complement activation on the surface of cells after incorporation of decayaccelerating factor (DAF) into their membranes. J. Exp. Med. 160:1558- 1578.
7. Sun L, Lu X, Li C, Wang M, Liu Q, Li Z, Hu X, Li J, Liu F, Li Q, Belser JA, Hancock K, Shu Y, Katz JM, Liang M, Li D. 2009. Generation, characterization and epitope mapping of two neutralizing and protective human recombinant antibodies against influenza A H5N1 viruses. PLoS One 4:e5476. doi:10.1371/journal.pone.0005476.
8. Tao Y, Strelkov SV, Mesyanzhinov VV, Rossmann MG. 1997. Structure of bacteriophage T4 fibritin: a segmented coiled coil and the role of the C-terminal domain. Structure 5:789 -798.
9. Freed EO, Myers DJ, Risser R. 1989. Mutational analysis of the cleavage sequence of the human immunodeficiency virus type 1 envelope glycoprotein precursor gp160. J. Virol. 63:4670-4675.
10. Guthe S, Kapinos L, Moglich A, Meier S, Grzesiek S, Kiefhaber T. 2004. Very fast folding and association of a trimerization domain from bacteriophage T4 fibritin. J. Mol. Biol. 337:905-915.
11. Yang X, Lee J, Mahony EM, Kwong PD, Wyatt R, Sodroski J. 2002. Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J. Virol. 76:4634-4642.
12. Follenzi A, Ailles LE, Bakovic S, Geuna M, Naldini L. 2000. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat. Genet. 25:217-222.
13. Li Y, Kappes JC, Conway JA, Price RW, Shaw GM, Hahn BH. 1991.Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication- competent and -defective viral genomes. J. Virol. 65:3973-3985.
14. Wen M, Arora R, Wang H, Liu L, Kimata JT, Zhou P. 2010. GPIanchored single chain Fv-an effective way to capture transiently-exposed neutralization epitopes on HIV-1 envelope spike. Retrovirology 7:79. doi: 10.1186/1742-4690-7-79.
15. He J, Choe S, Walker R, Di Marzio P, Morgan DO, Landau NR. 1995. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J. Virol. 69:6705- 6711.
16. Kothe DL, Decker JM, Li Y, Weng Z, Bibollet-Ruche F, Zammit KP, Salazar MG, Chen Y, Salazar-Gonzalez JF, Moldoveanu Z, Mestecky J, Gao F, Haynes BF, Shaw GM, Muldoon M, Korber BTM, Hahn BH. 2007. Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. Virology 360:218 -234.
17. Overbaugh J, Anderson RJ, Ndinya-Achola JO, Kreiss JK. 1996. Distinct but related human immunodeficiency virus type 1 variant populations in genital secretions and blood. AIDS Res. Hum. Retroviruses 12:107-115.
18. Shang H, Han X, Shi X, Zuo T, Goldin M, Chen D, Han B, Sun W, Wu H, Wang X, Zhang L. 2011. Genetic and neutralization sensitivity of diverse HIV-1 env clones from chronically infected patients in China. J. Biol. Chem. 286:14531-14541.
19. Theodore TS, Englund G, Buckler-White A, Buckler CE, Martin MA, Peden KW. 1996. Construction and characterization of a stable fulllength macrophage-tropic HIV type 1 molecular clone that directs the production of high titers of progeny virions. AIDS Res. Hum. Retroviruses 12:191-194.
20. Miller AD, Chen F. 1996. Retrovirus packaging cells based on 10A1 murine leukemia virus for production of vectors that use multiple receptors for cell entry. J. Virol. 70:5564 -5571.
21. Tsai C, Caillet C, Hu H, Zhou F, Ding H, Zhang G, Zhou B, Wang S, Lu S, Buchy P, Deubel V, Vogel FR, Zhou P. 2009. Measurement of neutralizing antibody responses against H5N1 clades in immunized mice and ferrets using pseudotypes expressing influenza hemagglutinin and neuraminidase. Vaccine 27:6777- 6790.
22. Kimata JT, Kuller L, Anderson DB, Dailey P, Overbaugh J. 1999. Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression. Nat. Med. 5:535-541.
23. Frank S, Kammerer RA, Mechling D, Schulthess T, Landwehr R, Bann J, Guo Y, Lustig A, Bachinger HP, Engel J. 2001. Stabilization of short collagen-like triple helices by protein engineering. J. Mol. Biol. 308:1081- 1089.
24. Koyanagi Y, Miles S, Mitsuyasu R, Merrill J, Vinters H, Chen I. 1987. Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science 236:819-822.
25. Habazettl J, Reiner A, Kiefhaber T. 2009. NMR structure of a monomeric intermediate on the evolutionarily optimized assembly pathway of a small trimerization domain. J. Mol. Biol. 389:103-114.
26. McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, Khayat R, Louder R, Pejchal R, Sastry M, Dai K, O'Dell S, Patel N, SShahzad-ul- Hussan Yang Y, Zhang B, Zhou T, Zhu J, Boyington JC, Chuang GY, Diwanji D, Georgiev I, Kwon YD, Lee D, Louder MK, Moquin S, Schmidt SD, Yang ZY, Bonsignori M, Crump JA, Kapiga SH, Sam NE, Haynes BF, Burton DR, Koff WC, Walker LM, Phogat S, Wyatt R, Orwenyo J, Wang LX, Arthos J, Bewley CA, Mascola JR, Nabel GJ, Schief WR, Ward AB, Wilson IA, Kwong PD. 2011. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480:336 -343.
27. DiGiusto DL, Krishnan A, Li L, Li H, Li S, Rao A, Mi S, Yam P, Stinson S, Kalos M, Alvarnas J, Lacey SF, Yee JK, Li M, Couture L, Hsu D, Forman SJ, Rossi JJ, Zaia JA. 2010. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci. Transl. Med. 2:36ra43. doi:10.1126/scitranslmed.3000931.